Carl H. Rose, M.D.

Location

Contact

SUMMARY

Carl H. Rose, M.D., is a maternal-fetal medicine doctor whose research interests include fetal and maternal care, with particular focus on maternal adult congenital cardiac disease and maternal oncology in pregnancy. At present Dr. Rose is the principal investigator on a study to determine the prognostic value of the serum levels of a substance created by the heart — N-terminal pro-B-type natriuretic peptide (NT-proBNP) — when patients with maternal adult congenital cardiac disease are admitted with complications during or after giving birth.

Focus areas

• Standardization of preterm labor evaluation. Dr. Rose uses contemporary screening techniques to standardize both initial evaluation and admission criteria for patients presenting with preterm labor symptoms. His research has concluded that the proposed techniques resulted in a 56% reduction in hospital admission.

• NT-proBNP and adult congenital cardiac disease. NT-proBNP levels in midpregnancy often indicate that patients with adult congenital cardiac disease are less likely to develop maternal cardiovascular complications before giving birth; that is, NT-proBNP levels at midpregnancy have a high negative predictive value on antepartum cardiovascular complications.

  Dr. Rose is the principal investigator of a study examining patients' NT-proBNP levels at the time of admission in relation to later cardiovascular complications. His goal is to determine if the high negative predictive value of NT-proBNP levels remains valid in cardiovascular complications at the time of or after giving birth.

Significance to patient care

Currently, many people with adult congenital cardiac disease are admitted to the intensive care unit following delivery of their babies. They stay for 24 to 48 hours to be monitored for cardiac decompensation. If NT-proBNP values are found to have a high negative predictive value for cardiac complications, this could potentially avoid the necessity for intensive care unit admission for a significant patient population.

Professional highlights

• Principal investigator, NT-proBNP levels in the Prediction of Intrapartum and Postpartum Events in Adult Congenital Heart Disease Patients, Department of Obstetrics and Gynecology, Mayo Clinic, 2019-present
• Director, Maternal Fetal Medicine Fellowship, Mayo Clinic, Rochester, Minnesota, 2017-present
• Obstetrics & Gynecology journal
  • Editorial Board Member, 2021-2025
  • Reviewer, 2005-present